Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talacotuzumab in Systemic Lupus Erythematosus
NCT02920424Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of talacotuzumab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Subjects With Treatment-Emergent Adverse Events at 16 weeks and Percentage of Subjects With Systemic Administration-Related Reactions at 16 weeks. Planned start Jun 2017; status: withdrawn.
02
Drugs
talacotuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02920424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920424.